Friday, 20 Apr 2018

You are here

The RheumNow Week in Review – 2 June 2017

Dr. Jack Cush reviews highlights from the past week on 

  1. 108 Early RA pts (<6 mos) 41% use CAM/nutraceutical.CAM & higher DAS28 had 7 mo DMARD delay; Higher HAQ levels associated with shorter delay in DMARD use.
  2. 33 pts with Axial Spondyloarthritis Rx with NSAIDs decreased their MRI sacroiliitis and BM edema with longterm NSAIDs only
  3. Scleroderma Lung Study I/II CTX and MMF were associated with significant reductions in skin thickness compared to PBO @2yrs
  4. Rare MTX-induced skin necrosis w/ skin erosions, oral ulcers, cytopenia, 17% mortality. @Ris =age>60, CRI, no folate
  5. VINDICATE mnemonic for AVN causes: Vascular, Infection, Drugs, Inflamm, Congenital, Autoimmune, Trauma, Endocrine
  6. RA pregnant women shown to increase type 1 interferon gene expression from pre-preg to 3rd trimester
  7. 23% of adult rheumatologists care for kids w/ JIA. 94% are comfortable diagnosing JIA; 76% comfortable treating JIA
  8. New BSR 2017 British Society of.Rheumatology releases new guideline for Rx of gout; noting curative ULT must be offered to all pts early.
  9. Biologics Before Triple DMARD is Not Cost Effective in Rheumatoid Arthritis 
  10. High Fiber Intake May Decrease Osteoarthritis Knee Pain
  11.  Chondroitin Effective in Knee OA. Or is it?
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.